Portola Pharmaceuticals (NASDAQ:PTLA)‘s stock had its “buy” rating reaffirmed by William Blair in a research note issued to investors on Wednesday.

Several other analysts also recently issued reports on the company. ValuEngine upgraded Portola Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, May 29th. Zacks Investment Research upgraded Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 4th. Oppenheimer set a $60.00 price objective on Portola Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, August 26th. Credit Suisse Group restated an “underperform” rating and set a $28.00 price objective (down previously from $49.00) on shares of Portola Pharmaceuticals in a report on Friday, August 10th. Finally, Citigroup cut their price objective on Portola Pharmaceuticals from $64.00 to $50.00 and set a “buy” rating on the stock in a report on Friday, August 10th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $52.17.

Portola Pharmaceuticals stock traded up $0.88 during midday trading on Wednesday, hitting $29.67. The company’s stock had a trading volume of 33,082 shares, compared to its average volume of 1,353,473. The company has a current ratio of 6.69, a quick ratio of 6.59 and a debt-to-equity ratio of 0.91. Portola Pharmaceuticals has a 12 month low of $24.63 and a 12 month high of $57.70. The stock has a market cap of $1.82 billion, a PE ratio of -6.21 and a beta of 1.70.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($1.61) EPS for the quarter, missing the consensus estimate of ($1.49) by ($0.12). The business had revenue of $4.01 million during the quarter, compared to the consensus estimate of $6.35 million. Portola Pharmaceuticals had a negative return on equity of 111.64% and a negative net margin of 1,503.29%. Portola Pharmaceuticals’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.22) earnings per share. equities analysts predict that Portola Pharmaceuticals will post -5.77 EPS for the current fiscal year.

In other Portola Pharmaceuticals news, Director Jeffrey W. Bird bought 137,563 shares of the stock in a transaction on Tuesday, August 21st. The shares were bought at an average price of $25.17 per share, with a total value of $3,462,460.71. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jeffrey W. Bird bought 390,000 shares of the stock in a transaction on Thursday, August 23rd. The shares were acquired at an average cost of $25.84 per share, for a total transaction of $10,077,600.00. The disclosure for this purchase can be found here. Insiders own 4.60% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new position in Portola Pharmaceuticals during the 1st quarter valued at about $128,000. SeaCrest Wealth Management LLC purchased a new position in Portola Pharmaceuticals during the 2nd quarter valued at about $191,000. BB&T Securities LLC purchased a new position in Portola Pharmaceuticals during the 2nd quarter valued at about $201,000. Silvant Capital Management LLC purchased a new position in Portola Pharmaceuticals during the 1st quarter valued at about $186,000. Finally, Oppenheimer Asset Management Inc. purchased a new position in Portola Pharmaceuticals during the 2nd quarter valued at about $230,000. 94.26% of the stock is currently owned by institutional investors.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers.

Featured Article: Find a Trading Strategy That Works

Analyst Recommendations for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.